Article Text

PDF
SAT0100 Acpa and abdominal adiposity are independent predictors of increments in basal insulin in patients with ra
  1. E Gomez-Bañuelos1,
  2. K Arrona-Rios2,
  3. S Duran-Barragan3,
  4. L Gonzalez-Rosas2,
  5. J Aguilar-Arreola2,
  6. FDJ Perez-Vazquez1,
  7. G-I Diaz-Rubio1,
  8. E Chavarria-Avila1,
  9. F Corona-Meraz1,
  10. A Saldaña-Millan1,
  11. R-E Navarro-Hernandez1,
  12. M Vázquez-Del Mercado1,2
  1. 1Instituto de Invesgitaciόn en Reumatología y del Sistema Musculoesquelético, Universidad de Guadalajara
  2. 2Servicio de Reumatología, Divisiόn de Medicina interna, Pnpc 004086, CONACyT
  3. 3Instituto de Invesgitaciόn en Reumatología y del Sistema Musculoesquelético, Hospital Civil de Guadalajara, “Juan I. Menchaca”, Guadalajara, Mexico

Abstract

Background Insulin resistance (IR) is a comorbidity found in about 40%of RA patients. Currently, there is little information regarding the role of antibodies against citrullinated proteins and IR development in RA. Patients positive for ACPA and/or RF may be at higher risk of IR since these group of patients has a higher expression pro-inflammatory citokines like TNFa and IL-6, both implicated in the pathogenesis of IR.

Objectives To analyze the contribution of autoantibodies positivity (ACPA and/or RF) and their impact in the development of IR in patients with RA.

Methods We retrospectively analyzed patients classified with RA per ACR 1987 and ACR/EULAR 2010 criteria with at least one year of follow-up in a cohort of RA patients without comorbidities from Hospital Civil “Juan I. Menchaca”. DAS-28, basal insulin, HOMA-IR and anthropometric parameters: Body weight, body mass index (BMI), Sum 4 skinfold thicknesses (S4T), Waist to hip ratio (WHR), waist circumference (WC) and total fat mass (FM); were determined at current and baseline. Mean differences between the two time points were calculated. A multiple regression model was constructed considering mean insulin change as dependent variable.

Results We studied 57 RA patients, 44% (25) with IR and 56% (32) without IR. Of these, 21% (12) developed IR during follow-up. BMI, FM and ST4 were higher at baseline in patients with current IR at baseline. Ptients who developed IR during follow-up had a mean increase of DAS-28 of 1.27 (P<0.005 vs. patients who improved or never developed IR). Patients positive for ACPA had a greater increase in IR during follow-up. Multivariate analysis revealed that ACPA, increments in WHR and ST4 were independent predictors of basal insulin increases during follow-up.

Conclusions ACPA and abdominal adiposity (WHR) are independent predictors of IR development in RA

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.